Diese sind Teil des SURPASS-Studienprogramms
As part of peptide-based growth hormone release strategies, Ipamorelin contributes to muscle recovery, improved sleep quality, and metabolic efficiency
One example escalation schedule observed in Phase 2 obesity trials proceeded broadly as follows: Weeks 14: 2 mg once weekly (initiation phase) Weeks 58: 4 mg once weekly Weeks 912: 8 mg once weekly Weeks 13 onwards: Up to 12 mg once weekly (the maximum dose explored in Phase 2 trials) This is an illustrative example only
Many clients experience significant weight reduction, with an average weight loss of 15-20% of their body weight over the course of treatment
Track progress with a food diary or weight loss app
We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913)